neoSCB app to screen newborns for jaundice

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational project that takes smartphone photos of a newborn's sclera and applies a diagnostic algorithm to quantify yellowness as a marker of jaundice. Term infants up to 28 days old, with or without visible jaundice, will have scleral photographs taken and may undergo routine bilirubin testing as clinically required. The approach aims to reduce unnecessary hospital blood tests driven by imperfect visual inspection and to help identify infants needing timely treatment. The study is conducted at University College London Hospitals and builds on prior validation work in Ghana.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Term newborn babies with and without jaundice (postnatal age 0 day to 28 days)

Exclusion Criteria:

* Newborn babies who are clinically unwell and require urgent medical attention, and babies who have received phototherapy recently

Where it's running

• UCL Hospitals
  London, United Kingdom Recruiting

Study contacts

• Principal investigator: Judith Meek, MBBS — UCL Hospitals
• Study coordinator: Terence Leung, PhD
• Email: t.leung@ucl.ac.uk
• Phone: +442076790272

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abdominal Massage for Newborn Jaundice

  Tests whether infant abdominal massage, added to routine care, can lower bilirubin levels in healthy full-term newborns.

  Recruiting Taichung Veterans General Hospital · Taichung, Taiwan · NCT07747220

• BUBOLight® phototherapy device for treating newborn jaundice

  This will try the BUBOLight® textile-based phototherapy device on newborns with jaundice who need phototherapy.

  Recruiting University Hospital, Lille · Lille · NCT04365998

• Monitoring and Early Detection of Treatable Inherited Retinal Disease in Children and Adolescents

  This study tests AI tools to spot and track inherited retinal diseases caused by RPE65 and RPGR mutations using widefield eye images in kids and teens.

  Recruiting University College, London · Boston, Massachusetts and 2 other locations · NCT07901907

• Oral Progestin Tablets With Radiotherapy vs. Standard Radiotherapy and Chemotherapy in High-Risk NSMP Endometrial Cancer

  This trial tests whether adding oral progestin tablets after radiotherapy is as effective as the standard radiotherapy plus chemotherapy for high-risk NSMP endometrial cancer, hoping to reduce side effects and improve quality of life.

  Recruiting at 12 sites Phase 3 University College, London · Bath and 11 other locations · NCT07831902

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lower-dose ARPI therapy for metastatic prostate cancer

  This trial tests whether using half the usual dose of ARPI therapy can work as well as a full dose for men with metastatic prostate cancer who are also receiving standard hormone therapy.

  Recruiting at 4 sites Phase 3 University College, London · Huddersfield and 3 other locations · NCT07751133

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.